@article{f5d7378482e746db92ea9643222e85b3,
title = "Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.",
keywords = "PREVIOUSLY UNTREATED PATIENTS, OPEN-LABEL, FLOW-CYTOMETRY, INDEPENDENT PREDICTOR, RITUXIMAB REGIMEN, 1ST-LINE THERAPY, PROGRESSION-FREE, FREE SURVIVAL, END-POINT, PHASE-II",
author = "Wierda, {William G} and Andrew Rawstron and Florence Cymbalista and Xavier Badoux and Davide Rossi and Brown, {Jennifer R} and Alexander Egle and Virginia Abello and {Cervera Ceballos}, Eduardo and Yair Herishanu and Mulligan, {Stephen P} and Niemann, {Carsten U} and Diong, {Colin P} and Teoman Soysal and Ritsuro Suzuki and Tran, {Hoa T T} and Shang-Ju Wu and Carolyn Owen and Stephan Stilgenbauer and Paolo Ghia and Peter Hillmen",
note = "Egle: Department of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Salzburg, Austria",
year = "2021",
doi = "10.1038/s41375-021-01241-1",
language = "English",
volume = "35",
pages = "3059--3072",
journal = "LEUKEMIA ",
issn = "0887-6924",
number = "11",
}